AR024839A1 - Compuesto bi o triciclico sustituido, su uso en la fabricacion de un medicamento y composicion farmaceutica que lo comprende. - Google Patents

Compuesto bi o triciclico sustituido, su uso en la fabricacion de un medicamento y composicion farmaceutica que lo comprende.

Info

Publication number
AR024839A1
AR024839A1 ARP990105296A ARP990105296A AR024839A1 AR 024839 A1 AR024839 A1 AR 024839A1 AR P990105296 A ARP990105296 A AR P990105296A AR P990105296 A ARP990105296 A AR P990105296A AR 024839 A1 AR024839 A1 AR 024839A1
Authority
AR
Argentina
Prior art keywords
composition
substituted
manufacture
compound
triciclic
Prior art date
Application number
ARP990105296A
Other languages
English (en)
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22640811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR024839(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Searle & Co filed Critical Searle & Co
Publication of AR024839A1 publication Critical patent/AR024839A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Una clase de compuestos bi o triciclicos sustituidos y su uso en la fabricacion de medicamentos utiles en el tratamiento de afecciones mediadas porciclooxigenasa-2. Los compuestos de particular interés son los definidos por la formula 1 donde X, A1,A2, A3, A4, R, R, R1 y R2 tienen los valores definidosen la memoria descriptiva. Se describe asimismo la composicion farmacéutica que comprende dicho compuesto.
ARP990105296A 1998-10-20 1999-10-20 Compuesto bi o triciclico sustituido, su uso en la fabricacion de un medicamento y composicion farmaceutica que lo comprende. AR024839A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/175,584 US6077850A (en) 1997-04-21 1998-10-20 Substituted benzopyran analogs for the treatment of inflammation

Publications (1)

Publication Number Publication Date
AR024839A1 true AR024839A1 (es) 2002-10-30

Family

ID=22640811

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105296A AR024839A1 (es) 1998-10-20 1999-10-20 Compuesto bi o triciclico sustituido, su uso en la fabricacion de un medicamento y composicion farmaceutica que lo comprende.

Country Status (33)

Country Link
US (4) US6077850A (es)
EP (1) EP1123285A1 (es)
JP (1) JP2002527512A (es)
KR (1) KR20010086438A (es)
CN (1) CN1150181C (es)
AP (1) AP2001002143A0 (es)
AR (1) AR024839A1 (es)
AU (1) AU767655C (es)
BG (1) BG105513A (es)
BR (1) BR9914696A (es)
CA (1) CA2347910A1 (es)
CU (1) CU23029A3 (es)
CZ (1) CZ20011424A3 (es)
EA (1) EA005599B1 (es)
EE (1) EE200100227A (es)
GE (1) GEP20033027B (es)
HK (1) HK1040397B (es)
HR (1) HRP20010288A2 (es)
HU (1) HUP0104316A3 (es)
ID (1) ID30062A (es)
IL (1) IL142667A0 (es)
IS (1) IS5921A (es)
MY (1) MY138238A (es)
NO (1) NO20011940L (es)
NZ (1) NZ511593A (es)
OA (1) OA11912A (es)
PL (1) PL347384A1 (es)
SK (1) SK5412001A3 (es)
TR (1) TR200101969T2 (es)
TW (1) TWI250979B (es)
UA (1) UA75328C2 (es)
WO (1) WO2000023433A1 (es)
ZA (1) ZA200103200B (es)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034869A1 (fr) * 1996-03-18 1997-09-25 Eisai Co., Ltd. Derives de l'acide carboxylique a cycles fusionnes
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US20030225150A1 (en) * 1997-04-21 2003-12-04 Pharmacia Corporation Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US20030203956A1 (en) * 1998-12-23 2003-10-30 Masterrer Jaime L. Method of using a cyclooxygenase-2 inhibitor and one or more ornithine decarboxylase inhibitors as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
US20030119895A1 (en) * 1998-12-23 2003-06-26 Pharmacia Corporation Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
IL136025A0 (en) * 1999-05-14 2001-05-20 Pfizer Prod Inc Combination therapy for the treatment of migraine
CO5190664A1 (es) 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
WO2001049675A1 (en) * 2000-01-03 2001-07-12 Pharmacia Corporation Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
KR20030027016A (ko) * 2000-08-09 2003-04-03 에프. 호프만-라 로슈 아게 항-염증제로서의 퀴놀린 유도체
US20050143360A1 (en) * 2001-02-02 2005-06-30 Joel Krasnow Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea
EP1365753A2 (en) * 2001-02-02 2003-12-03 Pharmacia Corporation Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
US7012098B2 (en) * 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
WO2002078625A2 (en) * 2001-03-28 2002-10-10 Pharmacia Corporation Therapeutic combinations for cardiovascular and inflammatory indications
DE10121252A1 (de) * 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
US20030153801A1 (en) * 2001-05-29 2003-08-14 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
US20040067992A1 (en) * 2001-08-10 2004-04-08 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
US20030114416A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
US20050101563A1 (en) * 2001-08-14 2005-05-12 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation
AR038957A1 (es) * 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
US20030114483A1 (en) * 2001-09-18 2003-06-19 Pharmacia Corporation Compositions of chromene cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
US20030236308A1 (en) * 2001-09-18 2003-12-25 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
US7057049B2 (en) * 2001-09-25 2006-06-06 Pharmacia Corporation Process for making substituted pyrazoles
IL161009A0 (en) 2001-09-25 2004-08-31 Pharmacia Corp Process for making substituted pyrazoles
US20030211163A1 (en) * 2002-01-10 2003-11-13 Chong Kong Teck Combination antiviral therapy
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
TW200403072A (en) * 2002-01-23 2004-03-01 Upjohn Co Combination therapy for the treatment of bacterial infections
CA2481934A1 (en) * 2002-04-18 2003-10-30 Pharmacia Corporation Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
AU2003226379A1 (en) * 2002-04-18 2003-11-03 Pharmacia Corporation Treatment of parkinson's disease with cyclooxygenase-2 (cox 2) inhibitor(s)
GB0209257D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
JP2005535657A (ja) * 2002-07-02 2005-11-24 ファルマシア・コーポレーション シクロオキシゲナーゼ−２選択阻害剤及び血栓溶解剤の血管閉塞イベントの治療又は予防への使用
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
KR20070091049A (ko) 2002-12-13 2007-09-06 워너-램버트 캄파니 엘엘씨 하부요로증상을 치료하기 위한 알파-2-델타 리간드
US20040157848A1 (en) * 2002-12-19 2004-08-12 Pharmacia Corporation Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents
AU2003300264A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event
US20050026902A1 (en) * 2003-01-31 2005-02-03 Timothy Maziasz Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
US20040176378A1 (en) * 2003-02-12 2004-09-09 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an amphetamine for the treatment of reduced blood flow to the central nervous system
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20040214861A1 (en) * 2003-03-28 2004-10-28 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
US7259266B2 (en) 2003-03-31 2007-08-21 Pharmacia Corporation Benzopyran compounds useful for treating inflammatory conditions
WO2004093814A2 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a sodium channel blocker
US20050159403A1 (en) * 2003-04-22 2005-07-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage
WO2004093813A2 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
US20040229803A1 (en) * 2003-04-22 2004-11-18 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
WO2004093811A2 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of central nervous system damage
WO2004093896A1 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage
PL1745791T3 (pl) 2003-05-07 2013-11-29 Osteologix As Leczenie chorób chrząstki/kości za pomocą rozpuszczalnych w wodzie soli strontu
US20050107387A1 (en) * 2003-05-13 2005-05-19 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
US20050159419A1 (en) * 2003-05-14 2005-07-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
US20050026919A1 (en) * 2003-05-14 2005-02-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system
WO2004110456A1 (en) * 2003-05-27 2004-12-23 Pharmacia Corporation Fcompositions of a cyclooxygenase-2 selective inhibitor, a xanthine compound and an alcohol for the treatment of ischemic mediated central nervous system disorders or injury
US20060160776A1 (en) * 2003-05-28 2006-07-20 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
US20050054646A1 (en) * 2003-06-09 2005-03-10 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders
US20050065154A1 (en) * 2003-06-24 2005-03-24 Pharmacia Corporation Treatment of migraine accompanied by nausea with a combination of cyclooxygenase-2 selective inhibitors and anti-nausea agents
MXPA06000178A (es) * 2003-07-01 2006-04-11 Pharmacia & Upjohn Co Llc Solidos modulados en la fase de difusion.
WO2005007106A2 (en) * 2003-07-10 2005-01-27 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a non-nmda glutamate modulator for the treatment of central nervous system damage
US20050080083A1 (en) * 2003-07-10 2005-04-14 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin II receptor antagonist for the treatment of central nervous system damage
US20050080084A1 (en) * 2003-07-11 2005-04-14 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage
US20050070543A1 (en) * 2003-07-11 2005-03-31 Pharmacia Corporation Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050075341A1 (en) * 2003-07-17 2005-04-07 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
WO2005018564A2 (en) * 2003-08-22 2005-03-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
WO2005018563A2 (en) * 2003-08-22 2005-03-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
JP2007503396A (ja) * 2003-08-22 2007-02-22 ファルマシア コーポレイション 新形成の治療のためのシクロオキシゲナーゼ−２選択的阻害剤及びセロトニン−調節剤の組成物
US20050085479A1 (en) * 2003-08-27 2005-04-21 Pharmacia Corporation Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
US20050113409A1 (en) * 2003-09-03 2005-05-26 Pharmacia Corporation Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
EP1670417A2 (en) * 2003-10-03 2006-06-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischenic mediated central nervous system disorders or injury
CA2545731A1 (en) * 2003-11-12 2005-05-26 Pharmacia & Upjohn Company Compositions of a cyclooxygenase-2 selective inhibitor and a neurotrophic factor-modulating agent for the treatment of central nervous system mediated disorders
BRPI0506994A (pt) 2004-01-22 2007-07-03 Pfizer derivados de triazol que inibem a atividade antagonista da vasopressina
BRPI0510340A (pt) * 2004-04-28 2007-10-30 Pfizer derivados de 3-heterociclil-4-feniltriazol como inibidores do receptor via da vasopressina
JP2008507502A (ja) * 2004-07-23 2008-03-13 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 置換２−トリフルオロメチル−２ｈ−クロメン−３−カルボン酸誘導体を分離するためのエナンチオ選択的方法
EP1778662A1 (en) * 2004-07-23 2007-05-02 Warner-Lambert Company LLC Photoracemization of 2-trifluoromethyl-2h-chromene-3-carboxylic acid derivatives
WO2006011052A1 (en) * 2004-07-23 2006-02-02 Pharmacia & Upjohn Company Llc Method for the racemization of 2-trifluoro-2h-chromene-3-carboxylic acids
US7122700B2 (en) * 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
WO2006040672A1 (en) * 2004-10-12 2006-04-20 Pharmacia & Upjohn Company Llc Substituted cyclopropyl chromene compounds for use in the treatment and prevention of inflammation related conditions
WO2006040676A1 (en) * 2004-10-12 2006-04-20 Pharmacia & Upjohn Company Llc Nitrosated benzopyran compounds as novel cyclooxygenase-2 selective inhibitors
US20060128777A1 (en) * 2004-11-05 2006-06-15 Bendall Heather H Cancer treatments
US8048912B2 (en) * 2004-12-31 2011-11-01 Sk Chemicals Co., Ltd. Benzopyran derivatives having inhibitory activities against liver fibrosis and cirrhosis and their pharmaceutical uses
KR101135574B1 (ko) 2004-12-31 2012-04-23 한국화학연구원 간섬유화 및 간경화 억제 활성을 나타내는ν-(2,2-이중치환-2η-크로멘-6-일)싸이오우레아 유도체
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
WO2006088246A1 (ja) * 2005-02-18 2006-08-24 Takeda Pharmaceutical Company Limited Ｇｐｒ３４受容体機能調節剤
AU2006244393B2 (en) * 2005-05-05 2012-06-21 Cook Biotech Incorporated Implantable materials and methods for inhibiting tissue adhesion formation
TW200726746A (en) * 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
WO2008072801A1 (en) * 2006-12-13 2008-06-19 Seoul National University Industry Foundation Compounds with embedded benzopyran motif for core structures and preparation method thereof
UA94979C2 (uk) 2006-12-22 2011-06-25 Рекордати Айеленд Лимитед КОМБІНОВАНА ТЕРАПІЯ ПОРУШЕНЬ НИЖНІХ СЕЧОВИВІДНИХ ШЛЯХІВ ЛІГАНДАМИ α2δ І НПЗП
EP2114461A2 (en) * 2007-01-19 2009-11-11 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
AR072777A1 (es) * 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
US8426598B2 (en) * 2008-08-12 2013-04-23 Merck, Sharp & Dohme, Corp. N-heterocyclic M1 receptor positive allosteric modulators
AU2009296734B2 (en) * 2008-09-25 2016-02-18 Cephalon Llc Liquid formulations of bendamustine
EP2387400A1 (en) * 2009-01-15 2011-11-23 Cephalon, Inc. Novel forms of bendamustine free base
KR101292188B1 (ko) * 2009-03-27 2013-08-02 한국생명공학연구원 벤조피란 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물
ES2859676T3 (es) * 2011-10-18 2021-10-04 Askat Inc Composición medicinal
CN102757417B (zh) 2012-06-18 2014-09-24 中国科学院广州生物医药与健康研究院 氘代苯并吡喃类化合物及其应用
CN103044477B (zh) * 2012-12-07 2015-08-05 中国科学院广州生物医药与健康研究院 三甲基硅取代苯并吡喃类化合物及其应用
TWI646091B (zh) 2012-12-28 2019-01-01 日商衛斯克慧特股份有限公司 鹽類及晶形
EP3268085A4 (en) 2015-03-13 2018-10-31 The Board of Trustees of The Leland Stanford Junior University Ltb4 inhibition to prevent and treat human lymphedema
JP7062258B2 (ja) * 2019-01-22 2022-05-06 株式会社AskAt 溶解度の差を利用した、置換２ｈ－クロメン－３－カルボン酸の不斉変換方法
US20240165148A1 (en) 2021-03-15 2024-05-23 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
WO2023183406A1 (en) * 2022-03-22 2023-09-28 Regents Of The University Of Minnesota Therapeutic compound and salts
CN117384091B (zh) * 2023-12-08 2024-02-20 四川大学华西第二医院 一类酰胺衍生物、合成方法及用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046778A (en) * 1975-08-13 1977-09-06 Warner-Lambert Company Processes for the preparation of 4-hydroxy-2H-1-benzothiopyran-3-carboxamide 1,1-dioxides
JPH0232279B2 (ja) * 1982-08-12 1990-07-19 Kowa Co Jihidorobenzopiranjioorunoseiho
US4609744A (en) * 1983-04-21 1986-09-02 Merck Frosst Canada Inc. 4-oxo-benzopyran carboxylic acids
GB8323293D0 (en) * 1983-08-31 1983-10-05 Zyma Sa Substituted flavene and thioflavene derivatives
US4761425A (en) * 1983-12-27 1988-08-02 Merck Frosst Canada, Inc. Leukotriene antagonists
US4761424A (en) * 1985-10-01 1988-08-02 Warner-Lambert Company Enolamides, pharmaceutical compositions and methods for treating inflammation
GB8626344D0 (en) * 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
SE8605504D0 (sv) * 1986-12-19 1986-12-19 Astra Laekemedel Ab Novel chroman derivatives
US5264578A (en) * 1987-03-20 1993-11-23 Allergan, Inc. Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
JP2802996B2 (ja) * 1988-07-11 1998-09-24 興和株式会社 光学活性化合物の製造法
US5004744A (en) * 1988-12-13 1991-04-02 Bayer Aktiengesellschaft Pyridazinones as pesticides
US5082849A (en) * 1989-07-13 1992-01-21 Huang Fu Chich Quinolinyl-benzopyran derivatives as antagonists of leukotriene D4
US5155130A (en) * 1989-08-11 1992-10-13 Ciba-Geigy Corporation Certain benzopyran and benzothiopyran derivatives
EP0412939A3 (en) * 1989-08-11 1991-09-04 Ciba-Geigy Ag Certain benzopyran and benzothiopyran derivatives
MX9200299A (es) * 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
US5281720A (en) * 1991-02-28 1994-01-25 Merck Frosst Canada, Inc. Pyranylphenyl hydroxyalkylnaphthoic acids as inhibitors of leukotriene biosynthesis
US5250547A (en) * 1991-08-29 1993-10-05 Syntex (U.S.A.) Inc. Benzopyran derivatives
JP3283114B2 (ja) * 1992-09-07 2002-05-20 クミアイ化学工業株式会社 縮合ヘテロ環誘導体及び農園芸用殺菌剤
DK148392D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
IS4164A (is) * 1993-06-11 1994-12-12 Ab Astra Efnasambönd sem hindra flæði magasýru
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicycle compounds and pharmaceuticals containing them
GB9318431D0 (en) * 1993-09-06 1993-10-20 Boots Co Plc Therapeutic agents
SE9400809D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of quinoline-3-carboxamide compounds
DE69531458T2 (de) * 1994-05-27 2004-08-05 Glaxosmithkline S.P.A. Chinolinderivate als tachykinin nk3 rezeptor antagonisten
FR2731706B1 (fr) * 1995-03-14 1997-04-11 Cird Galderma Composes heterocycliques aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
JPH08337583A (ja) * 1995-04-13 1996-12-24 Takeda Chem Ind Ltd 複素環化合物およびその製造法
US5869478A (en) * 1995-06-07 1999-02-09 Bristol-Myers Squibb Company Sulfonamido substituted benzopyran derivatives
US5763470A (en) * 1995-06-07 1998-06-09 Sugen Inc. Benzopyran compounds and methods for their use
EP0841929B1 (en) * 1995-08-02 2003-05-07 Darwin Discovery Limited Quinolones and their therapeutic use
US5750564A (en) * 1995-09-12 1998-05-12 Hellberg; Mark Anti-oxidant esters of non-steroidal anti-inflammatory agents
CN1200114A (zh) * 1995-10-19 1998-11-25 武田药品工业株式会社 作为gnrh拮抗剂的喹啉衍生物
DE19613591A1 (de) * 1996-04-04 1997-10-09 Hoechst Ag Substituierte-Chinolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
CZ398598A3 (cs) * 1996-06-07 1999-07-14 The Procter & Gamble Company Dihydrobenzopyran, prostředek ho obsahující a způsob léčení zánětu nebo bolesti a artritidy
US6218427B1 (en) * 1996-08-27 2001-04-17 Shionogi & Co., Ltd. Chromene-3-carboxylate derivatives
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
WO1998034115A1 (en) * 1997-02-04 1998-08-06 Trega Biosciences, Inc. 4-substituted-quinoline derivatives and 4-substitute-quinoline combinatorial libraries
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
DE19755480A1 (de) * 1997-12-13 1999-06-24 Gruenenthal Gmbh Substituierte heterocyclische Benzocycloalkene und ihre Verwendung als analgetisch wirksame Substanzen
BR9916518A (pt) * 1998-12-23 2002-01-29 Searle & Co Método para tratar ou prevenir um distúrbio de neoplasia em um mamìfero em necessidade de tal tratamento ou prevenção, e, combinação compreendendo um inibidor de ciclooxigenase-2 e um ou mais agentes anti-neoplásticos

Also Published As

Publication number Publication date
BG105513A (en) 2001-12-29
IL142667A0 (en) 2002-03-10
PL347384A1 (en) 2002-04-08
HUP0104316A3 (en) 2002-11-28
CN1329607A (zh) 2002-01-02
US20020010206A1 (en) 2002-01-24
NO20011940D0 (no) 2001-04-19
US6077850A (en) 2000-06-20
AP2001002143A0 (en) 2001-04-15
EA005599B1 (ru) 2005-04-28
HK1040397B (zh) 2004-12-10
KR20010086438A (ko) 2001-09-12
CA2347910A1 (en) 2000-04-27
WO2000023433A1 (en) 2000-04-27
UA75328C2 (en) 2006-04-17
OA11912A (en) 2006-04-11
AU1092700A (en) 2000-05-08
EE200100227A (et) 2002-10-15
HUP0104316A2 (hu) 2002-04-29
IS5921A (is) 2001-04-18
TR200101969T2 (tr) 2001-10-22
CN1150181C (zh) 2004-05-19
BR9914696A (pt) 2002-02-05
WO2000023433A8 (en) 2000-07-27
NZ511593A (en) 2004-02-27
EP1123285A1 (en) 2001-08-16
NO20011940L (no) 2001-06-19
GEP20033027B (en) 2003-07-25
TWI250979B (en) 2006-03-11
SK5412001A3 (en) 2001-12-03
JP2002527512A (ja) 2002-08-27
ID30062A (id) 2001-11-01
CU23029A3 (es) 2005-02-23
HRP20010288A2 (en) 2002-06-30
US20040038977A1 (en) 2004-02-26
AU767655C (en) 2004-06-17
ZA200103200B (en) 2002-05-07
US7138411B2 (en) 2006-11-21
MY138238A (en) 2009-05-29
CZ20011424A3 (cs) 2001-10-17
EA200100451A1 (ru) 2001-10-22
HK1040397A1 (en) 2002-06-07
US6271253B1 (en) 2001-08-07
AU767655B2 (en) 2003-11-20
US6492390B2 (en) 2002-12-10

Similar Documents

Publication Publication Date Title
AR024839A1 (es) Compuesto bi o triciclico sustituido, su uso en la fabricacion de un medicamento y composicion farmaceutica que lo comprende.
BR1100860A (pt) Composto, droga antiinflamatória, composição farmacêutica, epìmero r e epìmero s do composto
AR066982A2 (es) Compuestos heteroaromaticos sustituidos como inhibidoress tirosin quinasa, composiciones farmaceuticas que los contiene y su uso en la preparacion de medicamentos
EE04799B1 (et) Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid
SE8300736D0 (sv) Novel pharmacologically active compounds
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
ATE242783T1 (de) Glycopeptid-derivate und pharmazeutische zusammensetzungen, die sie enthalten
BR1100987A (pt) Composto, composição farmacêutica da matéria, e, composição veterinária
MX9202166A (es) Derivados de amidino fenil alanina, procedimiento para su preparacion su empleo y agentes que los con tienen en calidad de anticoagulantes.
ATE148610T1 (de) Antimikrobielle mittel sowie substituierte 2- cyclohexan-1-yl-amin-derivate und deren herstellung
GR1000118B (el) Συνθεσις 1,2-διοξετανων & ενδιαμεσαι ουσιαι δι αυτην.
ES2107284T3 (es) Nuevas n-piridil-carboxamidas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
HUP0103203A2 (hu) Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
AR024118A1 (es) Compuesto de oxazolidinona biciclica como agentes antibacterianos, composicion farmaceutica que lo contiene y uso del mismo para la manufactura de un medicamento
ES2116612T3 (es) Nuevas bis-naftalimidas para el tratamiento del cancer.
IT1297205B1 (it) Composizioni farmaceutiche di somatostatina con assorbimento migliorato, loro preparazione e loro impiego
AR029637A1 (es) Compuestos de guanidina, antagonistas de los receptores de la il-8, una composicion farmaceutica que los contiene y el uso de los mismos para la manufactura de un medicamento
AR026523A1 (es) Uso de compuestos paa el tratamiento transdermico de infecciones bacterianas
IT8867891A0 (it) Derivati terziobutilati di benzilidene canfora procedimento per la loro preparazione,loro impiego come agenti anti ossidanti e composizioni cosmetiche e farmaceutiche che li contengono
CY1106712T1 (el) Υποκατεστημενα παραγωγα 5-αμινο-1-πεντεν-3-ολης
ITMI912261A1 (it) Composizioni farmaceutiche contenenti clozapina, loro preparazione e loro impiego
AR028987A1 (es) Compuesto derivado de ciclopentapiridin-cetona, composicion farmaceutica que lo contiene y su uso en la fabricacion de un medicamento util para tratar una enfermedad
RU94014631A (ru) Производные 4-хиномиодигидропиридина, смесь их изомеров или отдельные изомеры и их соли
IT1301679B1 (it) Derivati dell'iperforina, loro uso e formulazioni che licontengono.

Legal Events

Date Code Title Description
FB Suspension of granting procedure